GFM2

Across TCGA pan-cancer cohorts, GFM2 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated GFM2 data layer compared with 5 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher GFM2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated GFM2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and READ show a favorable association.

KIRC, STAD, and HNSC are the cancer types where GFM2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.701	0.559	<.001	86	view →
STAD	DFS	Median	IV	0.190	0.613	.002	44	view →
HNSC	DFS	Quartile	All	0.409	0.740	.001	41	view →
READ	OS	Tertile	III,IV	1.000	0.432	.005	19	view →
THCA	OS	Tertile	All	0.957	1.000	.011	16	view →
KICH	DFS	Median	II,III,IV	0.594	0.916	.008	15	view →
LGG	OS	Tertile	All	0.745	0.945	<.001	13	view →
ESCA	DFS	Tertile	IV	0.221	0.628	.024	13	view →
ACC	DFS	Quartile	All	0.412	0.795	.003	11	view →
BRCA	DFS	Quartile	All	0.490	0.580	.003	10	view →
SCLC	DFS	Median	III,IV	0.968	0.338	.024	8	view →
MESO	DFS	Quartile	All	0.264	0.456	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

GFM2–KIRC (OS)

Open the KIRC breakdown →